|
Gene: CEBPB |
Gene summary for CEBPB |
Gene summary. |
Gene information | Species | Human | Gene symbol | CEBPB | Gene ID | 1051 |
Gene name | CCAAT enhancer binding protein beta | |
Gene Alias | C/EBP-beta | |
Cytomap | 20q13.13 | |
Gene Type | protein-coding | GO ID | GO:0000003 | UniProtAcc | P17676 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
1051 | CEBPB | cSCC_p11 | Human | Skin | cSCC | 5.44e-18 | -6.28e-01 | -0.2102 |
1051 | CEBPB | cSCC_p3 | Human | Skin | cSCC | 7.92e-11 | -5.82e-01 | -0.2085 |
1051 | CEBPB | cSCC_p4 | Human | Skin | cSCC | 4.09e-21 | -6.88e-01 | -0.2022 |
1051 | CEBPB | cSCC_p6 | Human | Skin | cSCC | 1.22e-25 | -7.44e-01 | -0.1989 |
1051 | CEBPB | cSCC_p7 | Human | Skin | cSCC | 5.96e-06 | -5.96e-01 | -0.2332 |
1051 | CEBPB | cSCC_p8 | Human | Skin | cSCC | 4.43e-28 | -6.15e-01 | -0.1971 |
1051 | CEBPB | cSCC_p9 | Human | Skin | cSCC | 6.35e-25 | -6.45e-01 | -0.1991 |
1051 | CEBPB | Adj_PTCwithHT_6 | Human | Thyroid | HT | 5.95e-07 | -3.98e-01 | 0.02 |
1051 | CEBPB | Adj_PTCwithHT_8 | Human | Thyroid | HT | 1.61e-09 | -3.98e-01 | 0.0267 |
1051 | CEBPB | PTCwithHT_1 | Human | Thyroid | HT | 9.00e-03 | -3.98e-01 | 0.0238 |
1051 | CEBPB | PTCwithHT_6 | Human | Thyroid | HT | 5.95e-07 | -3.94e-01 | 0.02 |
1051 | CEBPB | PTCwithHT_8 | Human | Thyroid | HT | 5.95e-07 | -3.98e-01 | 0.0351 |
1051 | CEBPB | PTCwithoutHT_2 | Human | Thyroid | PTC | 1.28e-06 | -3.98e-01 | 0.0419 |
1051 | CEBPB | PTCwithoutHT_7 | Human | Thyroid | PTC | 9.00e-03 | -3.98e-01 | 0.0381 |
1051 | CEBPB | male-WTA | Human | Thyroid | PTC | 1.38e-58 | 2.86e-01 | 0.1037 |
1051 | CEBPB | PTC01 | Human | Thyroid | PTC | 2.45e-12 | 4.85e-01 | 0.1899 |
1051 | CEBPB | PTC04 | Human | Thyroid | PTC | 7.40e-15 | 1.00e+00 | 0.1927 |
1051 | CEBPB | PTC05 | Human | Thyroid | PTC | 9.60e-24 | 1.96e+00 | 0.2065 |
1051 | CEBPB | PTC06 | Human | Thyroid | PTC | 1.10e-40 | 1.68e+00 | 0.2057 |
1051 | CEBPB | PTC07 | Human | Thyroid | PTC | 3.71e-65 | 1.52e+00 | 0.2044 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00971939 | Breast | Precancer | intrinsic apoptotic signaling pathway | 59/1080 | 288/18723 | 8.07e-18 | 3.60e-15 | 59 |
GO:00709979 | Breast | Precancer | neuron death | 50/1080 | 361/18723 | 7.75e-09 | 5.70e-07 | 50 |
GO:00514029 | Breast | Precancer | neuron apoptotic process | 38/1080 | 246/18723 | 2.68e-08 | 1.75e-06 | 38 |
GO:00349769 | Breast | Precancer | response to endoplasmic reticulum stress | 38/1080 | 256/18723 | 7.89e-08 | 4.60e-06 | 38 |
GO:19012149 | Breast | Precancer | regulation of neuron death | 41/1080 | 319/18723 | 1.27e-06 | 4.80e-05 | 41 |
GO:00435237 | Breast | Precancer | regulation of neuron apoptotic process | 31/1080 | 212/18723 | 1.69e-06 | 6.08e-05 | 31 |
GO:00300999 | Breast | Precancer | myeloid cell differentiation | 45/1080 | 381/18723 | 4.00e-06 | 1.25e-04 | 45 |
GO:00018196 | Breast | Precancer | positive regulation of cytokine production | 52/1080 | 467/18723 | 4.18e-06 | 1.29e-04 | 52 |
GO:00022378 | Breast | Precancer | response to molecule of bacterial origin | 43/1080 | 363/18723 | 6.05e-06 | 1.72e-04 | 43 |
GO:00487329 | Breast | Precancer | gland development | 49/1080 | 436/18723 | 6.11e-06 | 1.73e-04 | 49 |
GO:00507293 | Breast | Precancer | positive regulation of inflammatory response | 23/1080 | 142/18723 | 6.51e-06 | 1.81e-04 | 23 |
GO:00436209 | Breast | Precancer | regulation of DNA-templated transcription in response to stress | 13/1080 | 53/18723 | 7.06e-06 | 1.95e-04 | 13 |
GO:00324968 | Breast | Precancer | response to lipopolysaccharide | 41/1080 | 343/18723 | 7.94e-06 | 2.17e-04 | 41 |
GO:00436189 | Breast | Precancer | regulation of transcription from RNA polymerase II promoter in response to stress | 12/1080 | 47/18723 | 1.02e-05 | 2.67e-04 | 12 |
GO:0050727 | Breast | Precancer | regulation of inflammatory response | 44/1080 | 386/18723 | 1.26e-05 | 3.22e-04 | 44 |
GO:00421107 | Breast | Precancer | T cell activation | 52/1080 | 487/18723 | 1.37e-05 | 3.42e-04 | 52 |
GO:00974216 | Breast | Precancer | liver regeneration | 10/1080 | 35/18723 | 1.91e-05 | 4.52e-04 | 10 |
GO:00456379 | Breast | Precancer | regulation of myeloid cell differentiation | 28/1080 | 210/18723 | 3.05e-05 | 6.72e-04 | 28 |
GO:00321034 | Breast | Precancer | positive regulation of response to external stimulus | 46/1080 | 427/18723 | 3.41e-05 | 7.40e-04 | 46 |
GO:19037069 | Breast | Precancer | regulation of hemopoiesis | 41/1080 | 367/18723 | 3.95e-05 | 8.52e-04 | 41 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0465716 | Breast | Precancer | IL-17 signaling pathway | 20/684 | 94/8465 | 4.74e-05 | 4.54e-04 | 3.48e-04 | 20 |
hsa0465717 | Breast | Precancer | IL-17 signaling pathway | 20/684 | 94/8465 | 4.74e-05 | 4.54e-04 | 3.48e-04 | 20 |
hsa0465721 | Breast | IDC | IL-17 signaling pathway | 18/867 | 94/8465 | 6.39e-03 | 3.30e-02 | 2.47e-02 | 18 |
hsa0465731 | Breast | IDC | IL-17 signaling pathway | 18/867 | 94/8465 | 6.39e-03 | 3.30e-02 | 2.47e-02 | 18 |
hsa05152 | Cervix | CC | Tuberculosis | 42/1267 | 180/8465 | 1.78e-03 | 7.21e-03 | 4.26e-03 | 42 |
hsa046686 | Cervix | CC | TNF signaling pathway | 28/1267 | 114/8465 | 4.60e-03 | 1.62e-02 | 9.59e-03 | 28 |
hsa051521 | Cervix | CC | Tuberculosis | 42/1267 | 180/8465 | 1.78e-03 | 7.21e-03 | 4.26e-03 | 42 |
hsa0466813 | Cervix | CC | TNF signaling pathway | 28/1267 | 114/8465 | 4.60e-03 | 1.62e-02 | 9.59e-03 | 28 |
hsa0465742 | Cervix | N_HPV | IL-17 signaling pathway | 16/349 | 94/8465 | 1.20e-06 | 1.64e-05 | 1.28e-05 | 16 |
hsa051524 | Cervix | N_HPV | Tuberculosis | 16/349 | 180/8465 | 3.05e-03 | 1.73e-02 | 1.35e-02 | 16 |
hsa0465752 | Cervix | N_HPV | IL-17 signaling pathway | 16/349 | 94/8465 | 1.20e-06 | 1.64e-05 | 1.28e-05 | 16 |
hsa051525 | Cervix | N_HPV | Tuberculosis | 16/349 | 180/8465 | 3.05e-03 | 1.73e-02 | 1.35e-02 | 16 |
hsa046687 | Endometrium | EEC | TNF signaling pathway | 27/1237 | 114/8465 | 6.47e-03 | 3.22e-02 | 2.40e-02 | 27 |
hsa0466814 | Endometrium | EEC | TNF signaling pathway | 27/1237 | 114/8465 | 6.47e-03 | 3.22e-02 | 2.40e-02 | 27 |
hsa0465726 | Esophagus | HGIN | IL-17 signaling pathway | 25/1383 | 94/8465 | 7.52e-03 | 4.63e-02 | 3.68e-02 | 25 |
hsa04657113 | Esophagus | HGIN | IL-17 signaling pathway | 25/1383 | 94/8465 | 7.52e-03 | 4.63e-02 | 3.68e-02 | 25 |
hsa0466810 | Esophagus | ESCC | TNF signaling pathway | 89/4205 | 114/8465 | 3.36e-10 | 4.01e-09 | 2.06e-09 | 89 |
hsa0465727 | Esophagus | ESCC | IL-17 signaling pathway | 66/4205 | 94/8465 | 3.93e-05 | 1.75e-04 | 8.99e-05 | 66 |
hsa051527 | Esophagus | ESCC | Tuberculosis | 111/4205 | 180/8465 | 7.14e-04 | 2.32e-03 | 1.19e-03 | 111 |
hsa052028 | Esophagus | ESCC | Transcriptional misregulation in cancer | 116/4205 | 193/8465 | 2.08e-03 | 5.95e-03 | 3.05e-03 | 116 |
Page: 1 2 3 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
CEBPB | ASC | Colorectum | MSS | RPS21,PMEPA1,SLC7A5, etc. | 4.19e-01 | |
CEBPB | STM | Oral cavity | Healthy | PTGES,MTHFD2L,TYMP, etc. | 4.29e-01 |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
CEBPB | SNV | Missense_Mutation | novel | c.879N>T | p.Lys293Asn | p.K293N | P17676 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-AZ-4315-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
CEBPB | SNV | Missense_Mutation | novel | c.803A>G | p.Asp268Gly | p.D268G | P17676 | protein_coding | deleterious(0) | possibly_damaging(0.823) | TCGA-EO-A22R-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
Page: 1 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |